Revance Wins FDA Approval for RHA Redensity Eye Filler
Nashville, Tennessee, August 20, 2026 Revance and Teoxane have announced FDA approval for RHA Redensity® Eye, a hyaluronic acid...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Nashville, Tennessee, August 20, 2026 Revance and Teoxane have announced FDA approval for RHA Redensity® Eye, a hyaluronic acid...
NASHVILLE, Tennessee, August 20, 2026 Harrow, Inc. announced positive results from a prospective, randomized contralateral-eye study evaluating IHEEZO® (chloroprocaine...
NASHVILLE, Tenn., August 6, 2026 Harrow Inc. announced it has entered into a definitive agreement to acquire the global...
ALISO VIEJO, Calif., July 6, 2026 Alcon and RxSight, Inc. have announced a strategic collaboration to jointly develop adjustable...
